No Data
No Data
Pailin Biotech (000403.SZ): Intravenous human immunoglobulin (10%) approved for clinical trials
Zhitong Finance App News, Pailin Biotech (000403.SZ) announced that Guangdong Shuanglin Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The name of the relevant drug is intravenous human immunoglobulin (10%), and it has agreed to carry out clinical trials with primary immune thrombocytopenia as the indication.
Yang Feng, shareholder of Pailin Biotech (000403.SZ), completed a reduction of 5.9985 million shares
Zhitong Finance App News, Pailin Biotech (000403.SZ) announced that Yang Feng, the shareholder of the company, reduced his holdings of the company's shares by a total of 5.9985 million shares, accounting for 0.82% of the total share capital. The implementation of this holdings reduction plan has been completed.
Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License
Pacific Shuanglin Bio-pharmacy's (SHE:000403) subsidiary Jixi Donghai Pacific Plasma Apheresis obtained a plasmapheresis license from health authorities in Heilongjiang province, China, according to a
Pailin Biotech (000403.SZ): Guangdong Shuanglin Phase II Project is expected to be put into operation in the second half of 2025, and the annual production capacity will increase to 1,500 tons
Gelonghui, May 9, 丨 Pailin Biotech (000403.SZ) held a performance briefing on May 7, 2024. Regarding “the expected increase in production capacity after the Guangdong Shuanglin production workshop construction project is put into operation,” the company replied that the Guangdong Shuanglin Phase II project is expected to be put into operation in the second half of 2025, and the annual production capacity will increase to 1,500 tons.
Pailin Biotech (000403.SZ): Slurry harvesting target is 1,400 tons in 2024
Gelonghui, May 9丨Pailin Biotech (000403.SZ) held a performance briefing on May 7, 2024. Regarding “How much plasma the company collects in 2023, how much plasma is expected to be collected in 2024?” The company replied that in 2023, the company's pulp collection volume will exceed 1,200 tons, and the scale of pulp collection will rank first in the kiloton level in the blood products industry; the target amount of pulp collection in 2024 is 1,400 tons.
Pailin Biotech (000403.SZ): Jixi Plasma Station obtained a single plasma collection license
On May 8, Ge Longhui (000403.SZ) announced that Jixi Donghai Pasfique Single Plasma Collection Co., Ltd. (“Jixi Pulp Station”), a wholly-owned subsidiary of the company, has received a “Single Plasma Collection License” issued by the Heilongjiang Provincial Health Commission.
No Data